Sustainable and equitable access to medicines
Health systems across Europe are facing growing pressures in how to meet the needs of patient access to medicine within confined health budgets.
A full and vigorous public debate is required on this subject therefore, involving all stakeholders, including healthcare professionals and patients, in order to create more sustainable and equitable means to provide patients in Europe with the medicines they need. EAHP see the need for inter-governmental dialogue at the EU and international level to underpin long term solutions and resolution.
Cost burden for medicines should not be transferred to greater extents upon the patient. This would represent a tax on ill health, and pose threats to adherence, early treatment and diagnosis and ultimately outcomes – a false 'saving'.
Greater transparency is required in the operation of pricing and reimbursement systems, including in respect to Research and Development components.
The hospital pharmacist's pharmacoeconomic skillset should be utilized in support of health technology assessment procedures. Hospital pharmacists are the secondary care sector experts in medicines use and the practice realities.
Care must be taken to ensure that certain cost-saving approaches such as generic tendering do not inadvertently result in supply chain vulnerability through over-vigorous deployment that results in diminished routes of supply.